SunTrust Banks, Inc. reaffirmed their buy rating on shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) in a report issued on Friday morning. The brokerage currently has a $10.00 price target on the biotechnology company’s stock.

A number of other analysts have also weighed in on ADAP. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC from a buy rating to a hold rating in a research note on Friday. TheStreet raised shares of Adaptimmune Therapeutics PLC from a d rating to a c rating in a research note on Thursday, November 2nd. BidaskClub raised shares of Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a research note on Sunday, July 16th. Leerink Swann reissued an outperform rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. Finally, ValuEngine raised shares of Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a research note on Thursday, July 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. Adaptimmune Therapeutics PLC presently has an average rating of Hold and an average price target of $11.58.

Shares of Adaptimmune Therapeutics PLC (NASDAQ ADAP) opened at $7.80 on Friday. Adaptimmune Therapeutics PLC has a one year low of $3.76 and a one year high of $9.29.

COPYRIGHT VIOLATION NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Rating Reiterated by SunTrust Banks, Inc.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/14/adaptimmune-therapeutics-plc-adap-rating-reiterated-by-suntrust-banks-inc.html.

Hedge funds have recently added to or reduced their stakes in the stock. KCG Holdings Inc. acquired a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $133,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Adaptimmune Therapeutics PLC during the third quarter valued at approximately $199,000. Paloma Partners Management Co acquired a new stake in shares of Adaptimmune Therapeutics PLC during the first quarter valued at approximately $165,000. OxFORD Asset Management LLP acquired a new stake in shares of Adaptimmune Therapeutics PLC during the second quarter valued at approximately $156,000. Finally, Virtu KCG Holdings LLC raised its holdings in shares of Adaptimmune Therapeutics PLC by 108.0% during the second quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock valued at $226,000 after acquiring an additional 26,105 shares during the period. 68.17% of the stock is owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.